A gene expression analysis of cancer cells exposed to that treatment identified Myc and Rac1, one of the critical factors in the maintenance of the intestinal barrier and upregulated in primary and metastatic CRCs [46], as major candidates driving acquired resistance. The gene discussed is RAC1; the disease is cancer.